

# VÃ©ronique Bouvier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10192133/publications.pdf>

Version: 2024-02-01

82  
papers

9,610  
citations

109137

35  
h-index

62479

80  
g-index

83  
all docs

83  
docs citations

83  
times ranked

15502  
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of non-clinical factors on restorative rectal cancer surgery: An analysis of four specialized population-based digestive cancer registries in France. <i>Digestive and Liver Disease</i> , 2022, 54, 258-267.	0.4	3
2	Cancer Among Adolescents and Young Adults Between 2000 and 2016 in France: Incidence and Improved Survival. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, 10, 29-45.	0.7	16
3	Association Between Use of Anticancer Drugs and Cardiovascular Disease-Related Hospitalization in Metastatic Colorectal Cancer: Insights From a Population-Based Study, the Anticancer Vigilance of Cardiac Events Study. <i>American Journal of Epidemiology</i> , 2021, 190, 376-385.	1.6	1
4	Same Chance of Accessing Resection? Impact of Socioeconomic Status on Resection Rates Among Patients with Pancreatic Adenocarcinoma—A Systematic Review. <i>Health Equity</i> , 2021, 5, 143-150.	0.8	9
5	What is the most appropriate period to define synchronous cancers?. <i>Cancer Epidemiology</i> , 2021, 71, 101900.	0.8	6
6	Multidisciplinary team meetings: are all patients presented and does it impact quality of care and survival — a registry-based study. <i>BMC Health Services Research</i> , 2021, 21, 1032.	0.9	15
7	Socioeconomic Environment and Survival in Patients with Digestive Cancers: A French Population-Based Study. <i>Cancers</i> , 2021, 13, 5156.	1.7	8
8	Trends in incidence of small bowel cancer according to histology: a population-based study. <i>Journal of Gastroenterology</i> , 2020, 55, 181-188.	2.3	17
9	Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1151-1159.	0.5	9
10	French LARS score™: validation of the French version of the low anterior resection syndrome (LARS) score for measuring bowel dysfunction after sphincter-preserving surgery among rectal cancer patients: a study protocol. <i>BMJ Open</i> , 2020, 10, e034251.	0.8	9
11	Analysis of medico-social factors for return to work among patients presenting with haematological malignancy (adamantine): results of a pilot study™. <i>BMC Research Notes</i> , 2020, 13, 313.	0.6	1
12	Cancer cure for 32 cancer types: results from the EUROCARE-5 study. <i>International Journal of Epidemiology</i> , 2020, 49, 1517-1525.	0.9	48
13	Cost-Effectiveness Analysis of a Mobile Mammography Unit for Breast Cancer Screening to Reduce Geographic and Social Health Inequalities. <i>Value in Health</i> , 2019, 22, 1111-1118.	0.1	7
14	Digestive and genitourinary sequelae in rectal cancer survivors and their impact on health-related quality of life: Outcome of a high-resolution population-based study. <i>Surgery</i> , 2019, 166, 327-335.	1.0	25
15	Time-to-cure and cure proportion in solid cancers in France. A population based study. <i>Cancer Epidemiology</i> , 2019, 60, 93-101.	0.8	16
16	Has adherence to treatment guidelines for mid/low rectal cancer affected the management of patients? A monocentric study of 604 consecutive patients. <i>Journal of Visceral Surgery</i> , 2019, 156, 281-290.	0.4	5
17	Influence of social deprivation and remoteness on the likelihood of sphincter amputation for rectal cancer: a high-resolution population-based study. <i>International Journal of Colorectal Disease</i> , 2019, 34, 927-931.	1.0	8
18	Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A population-based study. <i>Cancer Epidemiology</i> , 2019, 60, 106-111.	0.8	20

#	ARTICLE	IF	CITATIONS
19	Epidemiology of intrahepatic, perihilar, and distal cholangiocarcinoma in the French population. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 678-684.	0.8	13
20	Treatment challenges in and outside a network setting: Soft tissue sarcomas. <i>European Journal of Surgical Oncology</i> , 2019, 45, 31-39.	0.5	27
21	Epidemiology of rare cancers and inequalities in oncologic outcomes. <i>European Journal of Surgical Oncology</i> , 2019, 45, 3-11.	0.5	47
22	Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. <i>European Journal of Surgical Oncology</i> , 2019, 45, 46-51.	0.5	3
23	Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting. <i>European Journal of Surgical Oncology</i> , 2019, 45, 67-74.	0.5	22
24	Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. <i>European Journal of Surgical Oncology</i> , 2019, 45, 75-80.	0.5	15
25	Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. <i>European Journal of Surgical Oncology</i> , 2019, 45, 60-66.	0.5	4
26	Treatment challenges in and outside a network setting: Head and neck cancers. <i>European Journal of Surgical Oncology</i> , 2019, 45, 40-45.	0.5	27
27	Global surveillance of trends in cancer survival 2000â€“14 (CONCORD-3): analysis of individual records for 37â€“513â€“025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. <i>Lancet, The</i> , 2018, 391, 1023-1075.	6.3	3,228
28	Use of a case-mix approach to study the trends in the incidence of second primary cancers. <i>Annals of Epidemiology</i> , 2018, 28, 322-327.	0.9	3
29	Incidence and characteristics of chronic renal replacement therapy in patients with cancer: data from kidney and cancer registries in Basse-Normandie. <i>Journal of Nephrology</i> , 2018, 31, 111-118.	0.9	5
30	Survival of patients with cancer starting chronic dialysis: Data from kidney and cancer registries in lower Normandy. <i>Nephrology</i> , 2018, 23, 1125-1130.	0.7	6
31	No effect of comorbidities on the association between social deprivation and geographical access to the reference care center in the management of colon cancer. <i>Digestive and Liver Disease</i> , 2018, 50, 297-304.	0.4	11
32	Cost-Effectiveness Analysis of a Navigation Program for Colorectal Cancer Screening to Reduce Social Health Inequalities: A French Cluster Randomized Controlled Trial. <i>Value in Health</i> , 2018, 21, 685-691.	0.1	18
33	Socioeconomic status impacts survival and access to resection in pancreatic adenocarcinoma: A high-resolution population-based cancer registry study. <i>Surgical Oncology</i> , 2018, 27, 759-766.	0.8	16
34	Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991â€“2010 (Automated Childhood Cancer Information System): a population-based study. <i>Lancet Oncology, The</i> , 2018, 19, 1159-1169.	5.1	85
35	Development of a model to predict the 10-year cumulative risk of second primary cancer among cancer survivors. <i>Cancer Epidemiology</i> , 2017, 47, 35-41.	0.8	11
36	International incidence of childhood cancer, 2001â€“10: a population-based registry study. <i>Lancet Oncology, The</i> , 2017, 18, 719-731.	5.1	992

#	ARTICLE	IF	CITATIONS
37	Worldwide comparison of survival from childhood leukaemia for 1995â€“2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89â€ˆ828 children from 198 registries in 53 countries. <i>Lancet Haematology</i> , 2017, 4, e202-e217.	2.2	141
38	Could mobile mammography reduce social and geographic inequalities in breast cancer screening participation?. <i>Preventive Medicine</i> , 2017, 100, 84-88.	1.6	43
39	Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). <i>Gynecologic Oncology</i> , 2017, 144, 396-404.	0.6	93
40	The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). <i>Gynecologic Oncology</i> , 2017, 144, 405-413.	0.6	93
41	Methodological issues of assessing the risk of a second cancer occurring in the same site as a first cancer using registry data. <i>Cancer Epidemiology</i> , 2017, 51, 41-43.	0.8	5
42	Patient navigation to reduce social inequalities in colorectal cancer screening participation: A cluster randomized controlled trial. <i>Preventive Medicine</i> , 2017, 103, 76-83.	1.6	25
43	Burden and centralised treatment in Europe of rare tumours: results of RARECAREnetâ€™a population-based study. <i>Lancet Oncology</i> , 2017, 18, 1022-1039.	5.1	285
44	Risk of second primary cancer after a first potentially-human papillomavirus-related cancer: A population-based study. <i>Preventive Medicine</i> , 2016, 90, 52-58.	1.6	38
45	Pancreatic cancer: Wait times from presentation to treatment and survival in a populationâ€based study. <i>International Journal of Cancer</i> , 2016, 139, 1073-1080.	2.3	57
46	Trends in the risk of second primary cancer among bladder cancer survivors: a populationâ€based cohort of 10 047 patients. <i>BJU International</i> , 2016, 118, 53-59.	1.3	12
47	Influence of a screening navigation program on social inequalities in health beliefs about colorectal cancer screening. <i>Journal of Health Psychology</i> , 2016, 21, 1700-1710.	1.3	3
48	Survival of male genital cancers (prostate, testis and penis) in Europe 1999â€“2007: Results from the EURO CARE-5 study. <i>European Journal of Cancer</i> , 2015, 51, 2206-2216.	1.3	82
49	Age and case mix-standardised survival for all cancer patients in Europe 1999â€“2007: Results of EURO CARE-5, a population-based study. <i>European Journal of Cancer</i> , 2015, 51, 2120-2129.	1.3	66
50	Incidence and patterns of late recurrences in colon cancer patients. <i>International Journal of Cancer</i> , 2015, 137, 2133-2138.	2.3	46
51	Survival of adults with primary malignant brain tumours in Europe; Results of the EURO CARE-5 study. <i>European Journal of Cancer</i> , 2015, 51, 2231-2241.	1.3	56
52	Incidence and Patterns of Late Recurrences in Rectal Cancer Patients. <i>Annals of Surgical Oncology</i> , 2015, 22, 520-527.	0.7	18
53	Effect of previous history of cancer on survival of patients with a second cancer of the head and neck. <i>Oral Oncology</i> , 2015, 51, 457-463.	0.8	8
54	On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999â€“2007 â€ Results from the EURO CARE-5 study. <i>European Journal of Cancer</i> , 2015, 51, 2158-2168.	1.3	93

#	ARTICLE	IF	CITATIONS
55	Urinary tract cancer survival in Europe 1999â€“2007: Results of the population-based study EUROCORE-5. European Journal of Cancer, 2015, 51, 2217-2230.	1.3	75
56	Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCORE-5 population-based study. European Journal of Cancer, 2015, 51, 2130-2143.	1.3	344
57	Survival for oesophageal, stomach and small intestine cancers in Europe 1999â€“2007: Results from EUROCORE-5. European Journal of Cancer, 2015, 51, 2144-2157.	1.3	138
58	The EUROCORE-5 study on cancer survival in Europe 1999â€“2007: Database, quality checks and statistical analysis methods. European Journal of Cancer, 2015, 51, 2104-2119.	1.3	97
59	Survival patterns in lung and pleural cancer in Europe 1999â€“2007: Results from the EUROCORE-5 study. European Journal of Cancer, 2015, 51, 2242-2253.	1.3	73
60	Digestive cancers and occupational asbestos exposure: incidence study in a cohort of asbestos plant workers. Occupational and Environmental Medicine, 2015, 72, 792-797.	1.3	32
61	Survival of women with cancers of breast and genital organs in Europe 1999â€“2007: Results of the EUROCORE-5 study. European Journal of Cancer, 2015, 51, 2191-2205.	1.3	205
62	Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999â€“2007: Results of EUROCORE-5. European Journal of Cancer, 2015, 51, 2169-2178.	1.3	115
63	Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma. Leukemia and Lymphoma, 2015, 56, 2876-2882.	0.6	13
64	Survival of patients with skin melanoma in Europe increases further: Results of the EUROCORE-5 study. European Journal of Cancer, 2015, 51, 2179-2190.	1.3	80
65	Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000â€“2007: Results of EUROCORE-5 population-based study. European Journal of Cancer, 2015, 51, 2254-2268.	1.3	47
66	Global surveillance of cancer survival 1995â€“2009: analysis of individual data for 25â€“676â€“887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet, The, 2015, 385, 977-1010.	6.3	1,863
67	Management of rectal cancer in France in a well-defined population. European Journal of Gastroenterology and Hepatology, 2014, 26, 743-747.	0.8	5
68	Socioeconomic environment and cancer incidence: a French population-based study in Normandy. BMC Cancer, 2014, 14, 87.	1.1	57
69	The effect of patient characteristics on second primary cancer risk in France. BMC Cancer, 2014, 14, 94.	1.1	53
70	Patterns of adjuvant chemotherapy for stage II and III colon cancer in France and Italy. Digestive and Liver Disease, 2013, 45, 687-691.	0.4	7
71	A Population-based Comparison of Immunochemical Fecal Occult Blood Tests for Colorectal Cancer Screening. Gastroenterology, 2013, 144, 918-925.	0.6	56
72	Cancer Incidence and Survival in Adolescents and Young Adults in France, 2000â€“2008. Pediatric Hematology and Oncology, 2013, 30, 291-306.	0.3	60

#	ARTICLE	IF	CITATIONS
73	Volume of surgical activity and lymph node evaluation for patients with colorectal cancer in France. Digestive and Liver Disease, 2012, 44, 261-267.	0.4	16
74	Colorectal cancer screening: Why immunochemical faecal occult blood test performs as well with either one or two samples. Digestive and Liver Disease, 2012, 44, 694-699.	0.4	19
75	Cancer incidence within a cohort occupationally exposed to asbestos: a study of dose-response relationships. Occupational and Environmental Medicine, 2011, 68, 832-836.	1.3	29
76	Seasonal variations of immunochemical and guaiac faecal occult blood tests. Gut, 2011, 60, 423-424.	6.1	3
77	Socioeconomic and healthcare supply statistical determinants of compliance to mammography screening programs: A multilevel analysis in Calvados, France. Cancer Epidemiology, 2010, 34, 309-315.	0.8	45
78	Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: Performances of immunochemical colorectal cancer screening. International Journal of Technology Assessment in Health Care, 2010, 26, 48-53.	0.2	24
79	Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. International Journal of Cancer, 2009, 125, 1127-1133.	2.3	48
80	Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France. Health Economics (United Kingdom), 2004, 13, 227-238.	0.8	48
81	Re: Fecal Occult Blood Screening in the Minnesota Study. Journal of the National Cancer Institute, 1998, 90, 465-467.	3.0	0
82	Colorectal cancer mass-screening: Estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time. , 1997, 73, 220-224.		82